FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2135498635> ?p ?o ?g. }

• W2135498635 endingPage "102" @default.
• W2135498635 startingPage "93" @default.
• W2135498635 abstract "Cysteine proteases (falcipains), a papain-family of enzymes of Plasmodium falciparum, are responsible for haemoglobin degradation and thus necessary for its survival during asexual life cycle phase inside the human red blood cells while remaining non-functional for the human body. Therefore, these can act as potential targets for designing antimalarial drugs. The P. falciparum cysteine proteases, falcipain-II and falcipain- III are the enzymes which initiate the haemoglobin degradation, therefore, have been selected as targets. In the present study, we have designed new leupeptin analogues and subjected to virtual screening using Glide at the active site cavity of falcipain-II and falcipain-III to select the best docked analogues on the basis of Glide score and also compare with the result of AutoDock. The proposed analogues can be synthesized and tested in vivo as future potent antimalarial drugs.Protein falcipain-II and falcipain-III together with bounds inhibitors epoxysuccinate E64 (E64) and leupeptin respectively were retrieved from protein data bank (PDB) and latter leupeptin was used as lead molecule to design new analogues by using Ligbuilder software and refined the molecules on the basis of Lipinski rule of five and fitness score parameters. All the designed leupeptin analogues were screened via docking simulation at the active site cavity of falcipain-II and falcipain-III by using Glide software and AutoDock.The 104 new leupeptin-based antimalarial ligands were designed using structure-based drug designing approach with the help of Ligbuilder and subjected for virtual screening via docking simulation method against falcipain-II and falcipain-III receptor proteins. The Glide docking results suggest that the ligands namely result_037 shows good binding and other two, result_044 and result_042 show nearly similar binding than naturally occurring PDB bound ligand E64 against falcipain-II and in case of falcipain-III, 15 designed leupeptin analogues having better binding affinity compared to the PDB bound inhibitor of falcipain-III. The docking simulation results of falcipain-III with designed leupeptin analogues using Glide compared with AutoDock and find 80% similarity as better binder than leupeptin.These results further highlight new leupeptin analogues as promising future inhibitors for chemotherapeutic prevention of malaria. The result of Glide for falcipain-III has been compared with the result of AutoDock and finds very less differences in their order of binding affinity. Although there are no extra hydrogen bonds, however, equal number of hydrogen bonds with variable strength as compared to leupeptin along with the enhanced hydrophobic and electrostatic interactions in case of analogues supports our study that it holds the ligand molecules strongly within the receptor. The comparative e-pharmacophoric study also suggests and supports our predictions regarding the minimum features required in ligand molecule to behave as falcipain- III inhibitors and is also helpful in screening the large database as future antimalarial inhibitors." @default.
• W2135498635 created "2016-06-24" @default.
• W2135498635 creator A5012933760 @default.
• W2135498635 creator A5050966421 @default.
• W2135498635 creator A5090779423 @default.
• W2135498635 date "2013-09-03" @default.
• W2135498635 modified "2023-10-03" @default.
• W2135498635 title "Computation-based virtual screening for designing novel antimalarial drugs by targeting falcipain-III: a structure-based drug designing approach." @default.
• W2135498635 cites W1977724107 @default.
• W2135498635 cites W1982842980 @default.
• W2135498635 cites W1991512159 @default.
• W2135498635 cites W2012811752 @default.
• W2135498635 cites W2017640872 @default.
• W2135498635 cites W2029985793 @default.
• W2135498635 cites W2058820833 @default.
• W2135498635 cites W2067492598 @default.
• W2135498635 cites W2070828985 @default.
• W2135498635 cites W2074551970 @default.
• W2135498635 cites W2084527370 @default.
• W2135498635 cites W2097263871 @default.
• W2135498635 cites W2102377211 @default.
• W2135498635 cites W2102499150 @default.
• W2135498635 cites W2125677289 @default.
• W2135498635 cites W2135732933 @default.
• W2135498635 cites W2158534713 @default.
• W2135498635 cites W2160649586 @default.
• W2135498635 cites W2165174924 @default.
• W2135498635 cites W2016954252 @default.
• W2135498635 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23995310" @default.
• W2135498635 hasPublicationYear "2013" @default.
• W2135498635 type Work @default.
• W2135498635 sameAs 2135498635 @default.
• W2135498635 citedByCount "2" @default.
• W2135498635 countsByYear W21354986352014 @default.
• W2135498635 countsByYear W21354986352018 @default.
• W2135498635 crossrefType "journal-article" @default.
• W2135498635 hasAuthorship W2135498635A5012933760 @default.
• W2135498635 hasAuthorship W2135498635A5050966421 @default.
• W2135498635 hasAuthorship W2135498635A5090779423 @default.
• W2135498635 hasConcept C103697762 @default.
• W2135498635 hasConcept C104317684 @default.
• W2135498635 hasConcept C159110408 @default.
• W2135498635 hasConcept C181199279 @default.
• W2135498635 hasConcept C182220744 @default.
• W2135498635 hasConcept C185592680 @default.
• W2135498635 hasConcept C2775883766 @default.
• W2135498635 hasConcept C2775905019 @default.
• W2135498635 hasConcept C2776714187 @default.
• W2135498635 hasConcept C2777283782 @default.
• W2135498635 hasConcept C2780152424 @default.
• W2135498635 hasConcept C41685203 @default.
• W2135498635 hasConcept C55493867 @default.
• W2135498635 hasConcept C65556437 @default.
• W2135498635 hasConcept C71924100 @default.
• W2135498635 hasConcept C74187038 @default.
• W2135498635 hasConcept C86803240 @default.
• W2135498635 hasConceptScore W2135498635C103697762 @default.
• W2135498635 hasConceptScore W2135498635C104317684 @default.
• W2135498635 hasConceptScore W2135498635C159110408 @default.
• W2135498635 hasConceptScore W2135498635C181199279 @default.
• W2135498635 hasConceptScore W2135498635C182220744 @default.
• W2135498635 hasConceptScore W2135498635C185592680 @default.
• W2135498635 hasConceptScore W2135498635C2775883766 @default.
• W2135498635 hasConceptScore W2135498635C2775905019 @default.
• W2135498635 hasConceptScore W2135498635C2776714187 @default.
• W2135498635 hasConceptScore W2135498635C2777283782 @default.
• W2135498635 hasConceptScore W2135498635C2780152424 @default.
• W2135498635 hasConceptScore W2135498635C41685203 @default.
• W2135498635 hasConceptScore W2135498635C55493867 @default.
• W2135498635 hasConceptScore W2135498635C65556437 @default.
• W2135498635 hasConceptScore W2135498635C71924100 @default.
• W2135498635 hasConceptScore W2135498635C74187038 @default.
• W2135498635 hasConceptScore W2135498635C86803240 @default.
• W2135498635 hasIssue "2" @default.
• W2135498635 hasLocation W21354986351 @default.
• W2135498635 hasOpenAccess W2135498635 @default.
• W2135498635 hasPrimaryLocation W21354986351 @default.
• W2135498635 hasRelatedWork W1977724107 @default.
• W2135498635 hasRelatedWork W1997024873 @default.
• W2135498635 hasRelatedWork W2135498635 @default.
• W2135498635 hasRelatedWork W2150931400 @default.
• W2135498635 hasRelatedWork W2177551934 @default.
• W2135498635 hasRelatedWork W2345884960 @default.
• W2135498635 hasRelatedWork W2788126823 @default.
• W2135498635 hasRelatedWork W2977443319 @default.
• W2135498635 hasRelatedWork W4224105043 @default.
• W2135498635 hasRelatedWork W1966445083 @default.
• W2135498635 hasVolume "50" @default.
• W2135498635 isParatext "false" @default.
• W2135498635 isRetracted "false" @default.
• W2135498635 magId "2135498635" @default.
• W2135498635 workType "article" @default.